Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingNov 5, 2025HADLIMALack of Assurance of Sterility.Samsung Bioepis Co., Ltd. · D-0099-2026Class IIOngoingOct 29, 2025Taoscare Motion Sickness PatchesMarketed Without an Approved NDA/ANDAibspot · D-0098-2026Class IIOngoingOct 29, 2025OpdualagLack of Assurance of Sterility.Bristol-Myers Squibb Company · D-0097-2026Class IIOngoingOct 29, 2025Niacin Extended-release TabletsFailed Dissolution SpecificationsLannett Company Inc. · D-0096-2026Class IIOngoingOct 29, 2025ZICAM" MEDICATED FRUIT DROPS ELDERBERRY FLAVORLabeling: Label Mix-up: The product in the bottle contains elderberry and the label failed to indicate the inclusion of elderberry as an ingredient.Church & Dwight Co., Inc. · D-0095-2026Class IIOngoingOct 29, 2025Bupropion Hydrochloride Extended-Release Tablets USPFailed Tablet/Capsule SpecificationsGraviti Pharmaceuticals Private Limited · D-0037-2026Class IIOngoingOct 29, 2025Ketorolac Tromethamine InjectionPresence of Particulate Matter: Particulate matter identified as glassAspiro Pharma Limited · D-0036-2026Class IIOngoingOct 29, 2025Medline, Alcohol Prep PadsSubpotent DrugMedline Industries, LP · D-0035-2026Class IIOngoingOct 29, 2025Olopatadine Hydrochloride Ophthalmic Solution USP 0.1 %Failed Impurities/Degradation Specifications: The result for 'Any individual unspecified impurity' exceeds the specification limit.USV Private Limited · D-0034-2026Class IIIOngoingOct 29, 2025Cetirizine Hydrochloride Tablets USP 10 mgTablet/Capsules Imprinted with Wrong IDJB Chemicals and Pharmaceuticals Ltd · D-0033-2026Class IIIOngoingOct 29, 2025Cetirizine Hydrochloride Tablets USP 10 mgTablet/Capsules Imprinted with Wrong IDJB Chemicals and Pharmaceuticals Ltd · D-0032-2026Class IIOngoingOct 29, 2025Gabapentin CapsulesFailed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .The Harvard Drug Group LLC · D-0031-2026Class IIOngoingOct 29, 2025Gabapentin CapsulesFailed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .The Harvard Drug Group LLC · D-0030-2026Class IIOngoingOct 22, 2025CarbidopaProduct mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of...Rising Pharma Holding, Inc. · D-0029-2026Class IIOngoingOct 22, 2025FasenraLack of Assurance of Sterility:Astrazeneca Pharmaceuticals · D-0028-2026Class IIOngoingOct 22, 2025Sucralfate TabletsCGMP Deviations: The recalling firm filed for Chapter 11 on September 30, 2024. As a result, it cannot monitor the quality program and hence cannot assure that products...Amerisource Health Services LLC · D-0027-2026Class IIIOngoingOct 22, 2025Everolimus tablets 5mgFailed Impurities/Degradation Specifications: Out of specification for impurity IP-C.Endo USA, Inc. · D-0026-2026Class IIIOngoingOct 22, 2025FentaNYL Citrate PFLabeling: Incorrect or Missing Lot and/or Exp DateSTAQ Pharma, Inc. · D-0025-2026Class IIIOngoingOct 22, 2025Ketamine HydrochlorideLabeling: Incorrect or Missing Lot and/or Exp DateSTAQ Pharma, Inc. · D-0024-2026Class IIIOngoingOct 22, 2025Hydromorphone HCL PFLabeling: Incorrect or Missing Lot and/or Exp DateSTAQ Pharma, Inc. · D-0023-2026Class IIOngoingOct 22, 2025Aloe Up Sport Performance Sunscreen Lotion SPF 30cGMP deviations: the firm released and distributed product which failed total aerobic microbial count testing.SV Labs Prescott Corporation · D-0022-2026Class IIOngoingOct 22, 2025Viorele, Desogestrel and Ethinyl EstradiolFailed Impurities/Degradation SpecificationsGlenmark Pharmaceuticals Inc., USA · D-0021-2026Class IIOngoingOct 22, 2025Atorvastatin Calcium Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0020-2026Class IIOngoingOct 22, 2025Atorvastatin Calcium Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0019-2026Class IIOngoingOct 22, 2025Atorvastatin Calcium Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0018-2026Class IIOngoingOct 22, 2025Atorvastatin Calcium Tablets USPFailed Dissolution SpecificationsAscend Laboratories, LLC · D-0017-2026Class IIOngoingOct 22, 2025Tavaborole Topical solution 5%DiscolorationViona Pharmaceuticals Inc · D-0016-2026Class IOngoingOct 22, 2025Oxytocin 30 Units/500 mL in 0.9% Sodium Chloride for intravenous useSubpotent Drug: Testing revealed there was no oxytocin in the IV bag.IntegraDose Compounding Services LLC · D-0015-2026Class IOngoingOct 15, 2025NAD+ (Nicotinamide adenine dinucleotide) for InjectionMicrobial Contamination of Sterile Products: elevated endotoxin levelsGenoGenix LLC · D-0094-2026Class IIOngoingOct 15, 2025Retatrutide for InjectionLack of Assurance of SterilityGenoGenix LLC · D-0093-2026Class IIOngoingOct 15, 2025TirzepatideLack of Assurance of SterilityGenoGenix LLC · D-0092-2026Class IIOngoingOct 15, 2025Semaglutide for InjectionLack of Assurance of SterilityGenoGenix LLC · D-0091-2026Class IIOngoingOct 15, 2025Sermorelin Lyophilized powder for reconstitutionLack of Assurance of SterilityGenoGenix LLC · D-0090-2026Class IIOngoingOct 15, 2025Epithalon for InjectionLack of Assurance of SterilityGenoGenix LLC · D-0089-2026Class IIOngoingOct 15, 2025Tesamorelin for InjectionLack of Assurance of SterilityGenoGenix LLC · D-0088-2026Class IIOngoingOct 15, 2025Thymosin Beta-4Lack of Assurance of SterilityGenoGenix LLC · D-0087-2026Class IIOngoingOct 15, 2025BPC-157/Thymosin Beta-4 for InjectionLack of Assurance of SterilityGenoGenix LLC · D-0086-2026Class IIOngoingOct 15, 2025BPC-157 for InjectionLack of Assurance of SterilityGenoGenix LLC · D-0085-2026Class IIOngoingOct 15, 2025Zinc Chloride for InjectionLack of Assurance of SterilityGenoGenix LLC · D-0084-2026Class IIOngoingOct 15, 2025Semaglutide with B12 for InjectionLack of Assurance of SterilityGenoGenix LLC · D-0083-2026